Revvity Inc (BSP:R1VT34)
R$ 23.77 0 (0%) Market Cap: 81.00 Bil Enterprise Value: 93.46 Bil PE Ratio: 56.19 PB Ratio: 1.79 GF Score: 65/100

Revvity Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 06:30PM GMT
Release Date Price: R$18.75
Rachel Marie Vatnsdal Olson
JPMorgan Chase & Co, Research Division - Analyst

Perfect. Hi. Good afternoon, everyone. This is Rachel Vatnsdal from the life science tools and diagnostics team here at JPMorgan. I am joined on stage by Revvity and Prahlad, the CEO. So as is typical, this is going to be a 40-minute session. It will be roughly 20 minutes of a presentation followed by 20 minutes of Q&A. For any of you in the audience have questions, feel free to ping me.

With that, I will pass it off to Prahlad.

Prahlad R. Singh
Revvity, Inc. - CEO, President & Director

Good morning, everyone, and thank you, Rachel, for inviting us again to share our exciting story. And I also want to sort of commend you and your colleagues for being able to pull this off flawlessly year-over-year.

Before I begin, I wanted to invite your attention to our safe harbor statement and encourage you to visit the Investors section on our website, revvity.com for any forward-looking statements and additional disclosures that are made here today.

For

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot